专家简介：Richard S. Finn， MD， 美国加利福尼亚大学洛杉矶分校Geffen医学院教授，ILCA侯任主席，美 国 临 床 肿 瘤 学 会（ASCO）、美国癌症研究学会（AACR）成员，Clinical Cancer Research 杂志编委。主要研究领域涉及分子靶向治疗药物的研发以及肝癌、乳腺癌的分子学标志物研究。

 

　　“ILCA年会呈现了高水平的研究数据”

 

　　第九届国际肝癌学会（ILCA）年会非常精彩且难以超越，也是ILCA有史以来参会人数最多的一届。近年来，大会报告的质量越来越高。作为ILCA候任主席，深感责任重大。我们将力求保持其高标准和高规格，并努力使之越来越好，希望下届年会规模更大、参会人数更多，同时也希望ILCA成员继续壮大，期待下一届年会能与今年一样有高质量的会议报告呈现。

 

　　This was the 9th ILCA Conference and it really set the stage as a difficult act to follow. This was an excellent meeting. Attendance was very high; one the highest we have had. The quality of presentations at ILCA has only got better over the years. As the President of ILCA into the coming year， it is a lot of pressure to maintain these high standards and keep the organization growing. I would like to see the next meeting even bigger with greater attendance. I would like to see the membership of ILCA continue to grow. And I would like to see the same high quality data being presented at future meetings as well.

 

　　“肝癌TACE专场闪耀ILCA，期待肝癌各学科的全面发展”

 

　　肝癌TACE治疗专场集中了该领域非常优秀的专家学者，参会人员非常踊跃。会上，专家们重点阐述了仅三十年来TACE治疗的发展历程。显而易见，TACE在肝癌患者的治疗中占有重要地位。在肝癌患者的日常管理中，我们主要面临的问题包括：何时该停止TACE，哪些患者不应该接受TACE治疗，尤其当患者有节段性分支浸润时是否应该接受TACE治疗仍存在争议。研究表明，这些患者可通过索拉非尼治疗获益，然而在局部治疗手段不断更新以后，这些患者也同样可通过放射性栓塞治疗（Y90）获益。另一方面，随着TACE相关的新技术不断涌现，例如更好的导管给药方法、更好的成像技术和计算机程序，协助术者更接近肿瘤，以减轻药物毒性，希望能给患者带来更多的获益。此外，一种新的代谢复合物正在研发当做，它能通过作用于肿瘤增殖相关的酶来抑制肿瘤，并且可以通过肝动脉甚至全身（最近研究的结论）给药。

 

　　总之，肝癌在介入放射治疗方面有许多很好的研究，这是本届ILCA大会传递的重要信息。我们希望ILCA通过不断发展，不仅在肝病和肿瘤的医药领域，也希望在与肝癌相关的全科领域，包括外科和介入放射学科都有全面的发展。

 

　　Yesterday’s session on locoregional therapy and chemoembolization was very well attended. It was presented by excellent speakers in the field. It highlighted what we know， what we don’t know and how we are trying to figure it out. It is very clear that chemoembolization plays a critical role in the management of patients with liver cancer. Some of the questions in daily management we are dealing with are: when to stop TACE and who should not get TACE. There are areas of controversy where patients may have segmental branch invasion. The data suggests that these patients would benefit from sorafenib but now with newer locoregional techniques， there is perhaps a role for radioembolization (Y90). We also learned about some of the new technical aspects of TACE - better catheter delivery of drugs， better imaging techniques and computer programs that assist the operator in accessing tumors to limit toxicity and hopefully to get better outcomes. We learned about a new metabolic compound being developed that blocks some enzymes involved in tumor proliferation. This agent could be delivered via the hepatic artery or， based on recent developments， even systemically. So there is a lot of active research going on amongst the interventional radiology community and that is one of the take home messages from ILCA. We are looking at growing ILCA not only in the field of medical oncology and hepatology， but also to encompass the full multidisciplinary breadth of liver cancer represented， including surgery and interventional radiology.

 

　　“肝癌免疫治疗，一个值得期待的研究方向”

 

　　在ILCA会前会上，关于肿瘤免疫治疗的专题会议内容非常引人注目，有许多关于肿瘤免疫治疗药物研发的数据。在过去，肿瘤治疗药物的研发主要集中在肿瘤本身、肿瘤突变及肿瘤的信号通路方面的研究。而几十年来，研究者也从未停止在研究利用免疫系统攻击肿瘤方面的工作。近年来，肿瘤免疫治疗新药--针对程序性死亡受体（PD-1）和程序性死亡配体（PD-L1）的抗体药物nivolumab，已在黑素瘤、肺癌和其他类型肿瘤中获得成功。根据目前的初步资料分析，我们发现nivolumab可能在治疗肝癌患者方面同样有效。我们期待着更多关于肿瘤免疫治疗药物治疗早期及进展期肝癌的相关研究。

 

　　This morning’s pre-meeting session on immuno-oncology spent some time looking at some very exciting areas of drug development. Historically， drug development in cancer medicine has focused on the tumor， tumor mutations and signal transduction within the tumor. There has been an effort over decades to somehow harness the immune system to attack a patient’s tumor. In recent years， in melanoma， lung cancer and other cancer types， we have seen a new group of antibodies targeted against the programmed death receptor (PD-1) and programmed death-ligand (PD-L1). These antibodies look very active in these other diseases and we are now seeing preliminary data that one of these， nivolumab， may have activity in liver cancer and we look forward to more data on this class of drugs in both advanced and earlier stage disease.